PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:PCRX • US6951271005

20.47 USD
+0.11 (+0.54%)
Last: Feb 6, 2026, 10:22 AM
Fundamental Rating

6

PCRX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PCRX has an excellent profitability rating, but there are some minor concerns on its financial health. PCRX is cheap, but on the other hand it scores bad on growth. With these ratings, PCRX could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year PCRX was profitable.
  • PCRX had a positive operating cash flow in the past year.
  • Of the past 5 years PCRX 4 years were profitable.
  • PCRX had a positive operating cash flow in each of the past 5 years.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 1.65%, PCRX belongs to the top of the industry, outperforming 81.15% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 2.95%, PCRX belongs to the top of the industry, outperforming 82.20% of the companies in the same industry.
  • PCRX has a better Return On Invested Capital (3.63%) than 81.68% of its industry peers.
  • PCRX had an Average Return On Invested Capital over the past 3 years of 4.30%. This is significantly below the industry average of 12.87%.
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROIC 3.63%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 2.99%, PCRX is in the better half of the industry, outperforming 79.58% of the companies in the same industry.
  • PCRX has a Operating Margin of 8.88%. This is amongst the best in the industry. PCRX outperforms 80.63% of its industry peers.
  • PCRX's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 79.17%, PCRX belongs to the best of the industry, outperforming 84.29% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PCRX has remained more or less at the same level.
Industry RankSector Rank
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, PCRX has less shares outstanding
  • Compared to 5 years ago, PCRX has more shares outstanding
  • Compared to 1 year ago, PCRX has a worse debt to assets ratio.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

  • PCRX has an Altman-Z score of 1.84. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PCRX's Altman-Z score of 1.84 is in line compared to the rest of the industry. PCRX outperforms 59.16% of its industry peers.
  • The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 3.03, PCRX belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
  • PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
  • PCRX's Debt to Equity ratio of 0.52 is on the low side compared to the rest of the industry. PCRX is outperformed by 62.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Altman-Z 1.84
ROIC/WACC0.46
WACC7.95%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 5.26 indicates that PCRX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 5.26, PCRX is in the better half of the industry, outperforming 64.40% of the companies in the same industry.
  • PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 3.78, PCRX is in line with its industry, outperforming 59.69% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 3.78
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • PCRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.90%.
  • The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
  • Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -16.85% in the last year.
  • The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.01% on average over the next years.
  • The Revenue is expected to grow by 6.38% on average over the next years.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 6.89 indicates a rather cheap valuation of PCRX.
  • Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
  • PCRX is valuated cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • PCRX is valuated cheaply with a Price/Forward Earnings ratio of 5.89.
  • PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 93.19% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.20. PCRX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 6.89
Fwd PE 5.89
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 97.38% of the companies in the same industry.
  • PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 96.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.09
EV/EBITDA 5.87
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The decent profitability rating of PCRX may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.49
EPS Next 2Y4.05%
EPS Next 3Y6.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (2/6/2026, 10:22:52 AM)

20.47

+0.11 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)02-25
Inst Owners114.44%
Inst Owner Change-1.94%
Ins Owners0.79%
Ins Owner Change-1.85%
Market Cap880.62M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (48.07%)
Short Float %16.85%
Short Ratio7.81
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-20.55%
EPS NQ rev (1m)-0.63%
EPS NQ rev (3m)5.02%
EPS NY rev (1m)-0.31%
EPS NY rev (3m)3.58%
Revenue NQ rev (1m)-0.12%
Revenue NQ rev (3m)-2.05%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.99%
Valuation
Industry RankSector Rank
PE 6.89
Fwd PE 5.89
P/S 1.23
P/FCF 7.09
P/OCF 6.23
P/B 1.21
P/tB 2.71
EV/EBITDA 5.87
EPS(TTM)2.97
EY14.51%
EPS(NY)3.48
Fwd EY16.98%
FCF(TTM)2.89
FCFY14.1%
OCF(TTM)3.29
OCFY16.06%
SpS16.66
BVpS16.9
TBVpS7.54
PEG (NY)N/A
PEG (5Y)0.49
Graham Number33.61
Profitability
Industry RankSector Rank
ROA 1.65%
ROE 2.95%
ROCE 5.34%
ROIC 3.63%
ROICexc 4.58%
ROICexgc 7.99%
OM 8.88%
PM (TTM) 2.99%
GM 79.17%
FCFM 17.33%
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0.52
Debt/FCF 3.03
Debt/EBITDA 2.44
Cap/Depr 18.95%
Cap/Sales 2.4%
Interest Coverage 4.07
Cash Conversion 91.52%
Profit Quality 579.36%
Current Ratio 5.26
Quick Ratio 3.78
Altman-Z 1.84
F-Score7
WACC7.95%
ROIC/WACC0.46
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.38%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%

PACIRA BIOSCIENCES INC / PCRX FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


What is the valuation status for PCRX stock?

ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.


What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 6.89 and the Price/Book (PB) ratio is 1.21.